ADVISORY: Medical Device Recipients: Oversight Environment Questioned After Federal Contract Irregularity Involving ANAB

BRIDGEPORT, Conn. - April 2, 2026 - PRLog -- Daryl Guberman — a 40‑year Quality‑Systems Expert CEO of GUBERMAN‑PMC LLC, and Boeing Shareholder — has issued a formal advisory to medical device recipients, healthcare stakeholders, and patient‑safety advocates following the discovery of a significant irregularity involving ANAB and U.S. Department of State Work Order 19AQMM18R0131.

Important Advisory to Medical Device Recipients

This advisory highlights that products, materials, and components manufactured between 2018 and the present were produced inside an oversight environment now documented to contain a fraudulent irregularity — the ANAB underwriter representation revealed in the Guberman Anomaly-Discovery. https://guberman-quality.com/wp-content/uploads/2026/03/GUBERMAN-ANOMALY-FEBRUARY-2026.docx.pdf With each passing day, additional products continue to be manufactured under the same compromised accreditation conditions across industries worldwide. Until this oversight failure is addressed, the global system responsible for approving new items remains affected, a reality that requires immediate, proactive review from every manufacturer, supplier, end‑user, and citizen who relies on the integrity of that worldwide oversight chain.

However:

Oversight‑Affects‑Products

Because ANAB identified itself as an underwriter in a federal contract, on a private website, and in a technical publication, (pages 4-5 /GUBERMAN Anomaly Discovery)-the oversight environment directly affects medical devices manufactured between 2018 and the present. Devices made under those conditions fall within ANAB's claimed responsibility.

Devices produced in an environment where the accreditation chain contains false information are affected by that environment, even if they function properly.

A waiver from the FDA cannot undo fraudulent oversight conditions or retroactively validate approvals issued under a compromised accreditation environment.

There is no waiver, no exception, and no administrative workaround that can erase the consequences of falsified accreditation.

FDA Standards

• 21 CFR §820.180— Requires complete, accurate, truthful, and unaltered manufacturing and quality records.
• 21 CFR §820.70 — Requires validated processes and controlled environments; fraudulent accreditation invalidates process validation.
• 21 CFR §803.50 — Requires reporting of any condition that could cause serious injury or death, including fraudulent certification environments.

Oversight Environment, COMPROMISED!

Between 2018-2026, medical devices may have been manufactured under accreditation conditions now in question, including:

• ISO 13485 certifications
• MedAccred special‑process approvals
• Supply‑chain validations
• Quality‑system oversight tied to ANAB

The issue is systemic — tied to the oversight environment, and possible performance of individual devices.

Expanded Structural Findings, Regulatory Limits, and Global Impact

Structural Collapse: PRI- Performance Review Institute, MedAccred, NADCAP, ANAB

• MedAccred sits under PRI
• PRI-  sits under ANAB
• ANAB is tied to a false representation in a federal contract

When the top collapses, everything below it becomes contaminated.

Compounding Process‑Failure Effect on Parts and Devices (Medical & Aerospace)

From 2018–2026, every manufacturing step that relied on ANAB‑accredited or MRA/MLA‑equivalent international accreditation‑body oversight—heat‑treating, chemical processing, coating, machining, forming, assembly, sterilization, or final acceptance—was performed under an accreditation environment now documented as structurally compromised. In both aerospace and medical manufacturing and other industries, each process depends on the validity of the certification before it. When the foundational certification is fraudulent, every subsequent operation compounds the defect. A heat‑treated plate, a machined component, a coated airframe part, a sterilized implant, or a finished medical device may appear dimensionally correct, yet the chain of approvals behind it is invalid. The defect is not in the geometry of the part—it is in the integrity of the oversight system that approved every step. Once the root accreditation is compromised, every downstream process inherits that compromise, and no final inspection, test, or waiver can reverse the conditions under which the part or device was originally approved.

Integrated Oversight‑Affects‑Products Language

Medical devices manufactured between 2018 and the present are affected because the oversight system validating them was compromised. ANAB's self‑identification as an underwriter places responsibility on them for the conditions under which those devices were approved.

Regulatory Limits

• FDA cannot waive structural fraud
• False or misleading records invalidate approvals
• Structural fraud cannot be excused

Global Impact

• Mutual recognition structures spread contamination
• Rebranding does not erase historical oversight conditions

(January 2026- AS 9100 changed to AI9100, &  IAF-ILAC changed to GLOBAC )

"The world is rarely healed by institutions. It is healed by the one individual who sees the wound clearly enough — and cares deeply enough — to close it."
I have seen the wound.
I have mapped the fracture.
I am offering the repair.

2026 - Daryl Guberman